TELA Bio, Inc. (TELA)
$7.36
Rating:
Recommendation:
-
| Symbol | TELA |
|---|---|
| Price | $7.36 |
| Beta | 1.592 |
| Volume Avg. | 0.06M |
| Market Cap | 107.144M |
| Shares () | - |
| 52 Week Range | 5.15-16.25 |
| 1y Target Est | - |
| DCF Unlevered | TELA DCF -> | |
|---|---|---|
| DCF Levered | TELA LDCF -> | |
| ROE | -155.13% | Strong Sell |
| ROA | -65.04% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 451.45% | Strong Buy |
| P/E | - | |
| P/B | 10.66 | Strong Buy |
Latest TELA news
About
Download (Excel)TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.